Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

• DOI: 10.1136/thx.52.12.1030
• Publication Date: 2010-01-11T19:40:22Z
• Authors: T. F. Reiss; J. B. Hill; E. Harman; J. Zhang; W. K. Tanaka; E. Bronsky; D. Guerreiro; L. Hendeles
• Keywords: Leukotriene E4; Regimen; Crossover study

BACKGROUND: A study was undertaken to determine whether montelukast, a new potent cysteinyl leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction. The relationship between the urinary excretion of LTE4 and bronchoconstriction also investigated. METHODS: Nineteen non-smoking asthmatic patients with forced expiratory volume in one second (FEV1) > or = 65% predicted value reproducible fall FEV1 after exercise at least 20% were enrolled. Subjects received placebo montelukast 100 mg once daily evening 50 twice daily, each for two days, three-period, randomised, double blind, crossover design. In evening, approximately 20-24 hours dose 12 dose, standardised challenge performed. Data from 14 available complete analysis. RESULTS: mean (SD) maximal percentage decrease 29.6 (16.0), 17.1 (8.2), 14.0 (9.4) placebo, regimens, respectively. (95% CI) protection 37 (15 59) group who (31 69) those daily. Active treatments not different other. plasma concentrations higher regimen (1.27 (0.81) microgram/ml) than (0.12 (0.09) microgram/ml); there no correlation against concentrations. After increased significantly during treatment (from 34.3 73.7 pg/mg creatinine; p < 0.05) but did correlate extent CONCLUSIONS: Montelukast protects similarly 0.12 1.27 micrograms/ml. increase antagonist provide further evidence role leukotrienes pathogenesis